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Center, San Diego, CA, USA (269 in PREVENT TB, 11 in substudy); A Catanzaro, P LoBue, K Moser, M Tracy, P Francisco, J 
Davis; Montreal Chest Institute, Montreal, QC, Canada (267 in PREVENT TB, 9 in substudy): R I Menzies, K Schwartzman, C 
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PREVENT TB, 14 in substudy); J A Cayla, J M. Miró, M Antonia Sambeat, J L López Colomés, J A Martinez, X Martinez-Lacasa, A 
Orcau, P Sanchez, C Tortajada, I Ocana, J P Millet, A Moreno, J Nelson, O Sued, L de Souza, M A Jiménez, L del Baño, L Fina, L 
Roldan, A Romero; University of California, San Francisco, San Francisco, CA (199 in PREVENT TB, 4 in substudy): P Nahid, P 
Hopewell, C Daley, R Jasmer, C Merrifield, W Stanton, I Rudoy, J Israel; Johns Hopkins University, Baltimore, MD (210 in 
PREVENT TB, 20 in substudy): R E Chaisson, S E Dorman, J Hackman, G Maltas, J Fisher; Duke University/FHI 360, Durham, NC 
(183 in PREVENT TB, 12 in substudy): C D Hamilton, J Stout, A Mosher, E J Hecker, B Ho, E Rich; Boston University Medical 
Center, Boston, MA (171 in PREVENT TB, 0 in substudy): J Bernardo, J Saukkonen, C Murphy, D Brett-Curran; Edward Hines Jr VA 
Medical Center, Chicago, IL (174 in PREVENT TB, 11 in substudy): C T Pachucki, A Lee, S Marantz, M P Samuel, A Zulaga; 
Harlem Hospital Center, New York, NY (156 in PREVENT TB; 4 in substudy): W M El-Sadr, M Klein, C Badshah, J S Schicchi, Y 
Hirsh-Moverman; Emory University Department of Medicine, Atlanta, GA (114 in PREVENT TB, 4 in substudy): S M Ray, D P 
Holland, D Dixon, O Mohamed, K Folami, J Bush, C D Simpson, G Barika, W N Favors, N Snow; Jesse Brown VA Medical Center, 
Chicago, IL, USA (119 in PREVENT TB, 3 in substudy): M Bhattacharya, S Lippold, W Clapp, J Fabre; The University of British 
Columbia, Vancouver, BC, Canada (114 in PREVENT TB, 8 in substudy): J M Fitzgerald, K Elwood, E Hernandez, B Peyvandi, K 
Alasaly; VA Little Rock, Arkansas – Arkansas Department of Health, Little Rock, AR, USA (95 in PREVENT TB; 3 in substudy): I 
Bakhtawar, F Wilson, P Wassler, A Arnold, K Haden, J Owen; University of Manitoba, Winnipeg, MB, Canada (84 in PREVENT TB, 
7 in substudy): W Kepron, E Hershfield, M Roth, G A Izon; Michael E DeBakey VA Medical Center –Baylor College of Medicine, 
Houston, TX (60 in PREVENT TB, 4 in substudy): E Guy, C Lahart, T Scott, R Nickson; Washington DC Veterans Affairs Medical 
Center, Washington DC (31 in PREVENT TB, 3 in substudy): F Gordin, D Benator, D S Conwell; New York University Bellevue 
Hospital Center, New York, NY (33 in PREVENT TB, 1 in substudy): R Condos, W Rom, L Sandman; Walter Reed National Military 
Medical Center, Washington DC (13 in PREVENT TB): K Petersen, T Whitman; Prince George’s County Health Department, 
Cheverly, MD, USA (2 in PREVENT TB): T E Walsh, W Karney, A Adelakun.
A preliminary version of these results was presented at the 2011 American Thoracic Society Annual Meeting in Denver, CO, USA 
(abstract number 18812, ‘Hepatitis C virus infection and female sex are risk factors for treatment limiting hepatotoxicity in a large 
clinical trial of treatment of latent tuberculosis infection: results of a nested case-control study’ at Session C16: New tuberculosis 
treatment options for active and latent disease).
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SUMMARY
SETTING—Nine months of daily isoniazid (9H) and 3 months of once-weekly rifapentine plus 
isoniazid (3HP) are recommended treatments for latent tuberculous infection (LTBI). The risk 
profile for 3HP and the contribution of hepatitis C virus (HCV) infection to hepatotoxicity are 
unclear.
OBJECTIVES—To evaluate the hepatotoxicity risk associated with 3HP compared to 9H, and 
factors associated with hepatotoxicity
DESIGN—Hepatotoxicity was defined as aspartate aminotransferase (AST) >3 times the upper 
limit of normal (ULN) with symptoms (nausea, vomiting, jaundice, or fatigue), or AST >5 × ULN. 
We analyzed risk factors among adults who took at least 1 dose of their assigned treatment. A 
nested case-control study assessed the role of HCV.
RESULTS—Of 6862 participants, 77 (1.1%) developed hepatotoxicity; 52 (0.8%) were 
symptomatic; 1.8% (61/3317) were on 9H and 0.4% (15/3545) were on 3HP (P < 0.0001). Risk 
factors for hepatotoxicity were age, female sex, white race, non-Hispanic ethnicity, decreased 
body mass index, elevated baseline AST, and 9H. In the case-control study, HCV infection was 
associated with hepatotoxicity when controlling for other factors.
CONCLUSION—The risk of hepatotoxicity during LTBI treatment with 3HP was lower than the 
risk with 9H. HCV and elevated baseline AST were risk factors for hepatotoxicity. For persons 
with these risk factors, 3HP may be preferred.
Keywords
isoniazid; hepatitis C; aspartate aminotransferases
APPROXIMATELY ONE THIRD of the world’s population is infected with latent 
Mycobacterium tuberculosis.1 One of the main strategies for tuberculosis (TB) control and 
elimination is the treatment of latent tuberculous infection (LTBI) among persons at highest 
risk for progression to TB disease.2–5 While LTBI treatment is generally safe and well-
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tolerated, hepatotoxicity occurs in 0.1–4% of persons after initiating treatment.6 
Documented risk factors for hepatotoxicity include increasing age, elevated baseline 
transaminases, underlying liver disease, alcohol consumption, malnutrition, and being 
pregnant or in the immediate post-partum period.6 Hepatotoxicity may occur with all LTBI 
treatment regimens.6 Previous studies have found no consistent association between co-
infection with hepatitis B or C virus and increased hepatotoxicity incidence during LTBI 
treatment.7 The incidence of hepatotoxicity associated with 3 months of rifapentine (P, RPT) 
+isoniazid (H, INH) in PREVENT TB was 0.4%;8 however, risk factors for hepatotoxicity 
among persons receiving this regimen have not been previously reported.
To provide a more complete picture of the hepatotoxicity risk associated with LTBI 
treatment, including the hepatotoxicity-specific safety profile of 3 months of directly 
observed once-weekly RPT + INH (3HP), we examined treatment interruptions or 
discontinuations associated with LTBI treatment among adults enrolled in the Tuberculosis 
Trials Consortium’s PREVENT TB study. We also conducted a nested case-control study to 
evaluate the role of co-infection with chronic hepatitis C virus (HCV) in treatment-limiting 
hepatotoxicity.
METHODS
Definition of hepatotoxicity and clinical monitoring
Methods and primary findings for the PREVENT TB study have been published previously.8 
Analytic decisions made in determining risk factors (e.g., differentiating race from ethnicity) 
were similar between the main PREVENT TB study publication and this report to ensure 
comparability of published results. Study participants were enrolled from clinical trial sites 
in Brazil, Canada, Spain, and the United States. Participants from one PREVENT TB study 
site were excluded from this analysis due to discrepancies regarding receipt of study drug 
and directly observed therapy.
Monitoring for hepatotoxicity in the PREVENT TB study was primarily symptom-driven. 
Baseline and routine liver chemistries were drawn at the discretion of individual 
investigators per local guidelines and for participants at risk for hepatotoxicity.6 Participants 
were queried monthly about symptoms of nausea, vomiting, fatigue, or jaundice during 
study treatment. If hepatotoxicity was suspected, investigators were encouraged to query 
participants about alcohol use, and testing for viral hepatitis was suggested. Suspected 
hepatotoxicity events meeting the criteria of AST >3 times the upper limit of normal (ULN) 
with symptoms of nausea, vomiting, fatigue or jaundice, or AST >5 × ULN were 
systematically reported to the PREVENT TB study team at the US Centers for Disease 
Control and Prevention (CDC) via standardized adverse event case report forms. Toxicities 
were graded by local clinicians according to the Common Toxicity Criteria Version 2.9 
Events of AST >3 × ULN with symptoms were considered grade 3 toxicities. Treatment-
limiting hepatotoxicity was defined as the interruption of any study drug(s) for any length of 
time, including permanent discontinuation, as a result of suspected hepatotoxicity.
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Nested case-control study methods
For the nested case-control study, eligible case participants were those in the PREVENT TB 
study aged >18 years who experienced treatment-limiting hepatotoxicity. The primary 
objective of the nested study was to assess the effect of HCV co-infection on the 
discontinuation of LTBI treatment due to hepatotoxicity.
Study enrollment for the nested case-control study was open from March 2002 to November 
2009; 5.5% of adults enrolled in the PREVENT TB study were systematically selected as 
potential controls on enrollment into the PREVENT TB study. Age of potential control 
participants was evaluated for selection such that the mean age for all controls would be 45 
years, as isoniazid (INH) associated hepatotoxicity increases with age. If a selected control 
developed treatment-limiting hepatotoxicity, the participant was no longer considered a 
control and could instead be enrolled as a case.
All cases and controls provided written informed consent. The study was approved by the 
institutional review boards (IRBs) at all study sites and the CDC, Atlanta, GA, USA. One 
site was not IRB approved for the nested study and contributed no cases or controls.
Both case and control participants in the nested study were queried regarding alcohol use 
and concomitant medications in the month prior to enrollment; blood samples of all 
participants were collected for viral hepatitis serological testing at CDC. Blood specimens 
were tested for immunoglobulin (Ig) M antibody to hepatitis A virus (IgM anti-HAV), 
hepatitis B virus (HBV) surface antigen (HBsAg), total and IgM antibody to hepatitis B core 
(anti-HBc), and antibody to hepatitis C virus (anti-HCV). All positive anti-HCV specimens 
were subsequently tested using a nucleic acid test for HCV RNA (AMPLICOR® Hepatitis C 
Virus Test, v2.0; Roche Molecular Systems Inc, Branchburg, NJ, USA) to ascertain current 
unresolved HCV infection. HBV infection was defined as a positive HBsAg and negative 
IgM anti-HBc. Current (acute or chronic) HCV infection was defined as a positive anti-HCV 
antibody and HCV RNA, if available.
Statistical methods
For the analysis of incidence and risk factors for treatment-limiting hepatotoxicity, all 
participants aged ≥18 years enrolled in the PREVENT TB study between June 2001 and 
February 2008 who took at least one dose of the study drug were included. Statistical 
analyses were performed using SAS version 9.2 (Statistical Analysis System Institute, Cary, 
NC, USA). Race was reported by all trial participants, whereas ethnicity was reported only 
by participants in the United States or Canada. For descriptive analyses, all races were 
included; however, for modeling analyses, Asian/Pacific Islander, Black, and White were 
separate and North American Indian and other races were combined due to small numbers of 
North American Indian participants. Alcohol use was defined as self-reported current or past 
drinking of beer, wine or other alcoholic beverage in any amount. Alcohol abuse was defined 
as any affirmative response to the CAGE alcohol assessment questionnaire.10 History of 
chronic liver disease was defined as any self-reported hepatitis B or C, hepatitis due to 
alcohol use, or hepatitis or cirrhosis of unknown cause.
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We calculated hepatotoxicity incidence proportions and 95% confidence intervals (CIs) 
among adults in the PREVENT TB study. Incidence proportions were statistically compared 
using CIs. Using a Wilcoxon-Gehan test, Kaplan-Meier survival analysis was performed to 
compare days from treatment start to hepatotoxicity event. For comparisons of persons with 
and without hepatotoxicity, dichotomous variables were compared using Pearson’s χ2 or 
Fisher’s exact test. Multiplicative interactions of treatment regimen and participant factors 
were explored; none were statistically significant. Continuous variables were compared 
using Student’s t-test. For the analysis of risk factors for hepatotoxicity among adults in 
PREVENT TB, risk ratios (RRs) and 95%CIs were estimated using log-binomial regression. 
For the nested study, odds ratios (ORs) and 95%CIs were estimated using logistic 
regression. For multivariable modeling, all variables with P < 0.20 were entered into an 
initial model, and only those with P ≤ 0.05, through backwards selection, were retained in 
the final model. The multivariable model for the PREVENT TB study cohort omitted HCV 
co-infection, as these data were routinely collected only for nested study participants. The 
multivariable model for the case-control study excluded age because control participants 
were weighted by age and elevated baseline AST. Baseline AST was missing for 24% of the 
study population. We tested for co-linearity of risk factors included in multivariable models, 
and found that factors describing liver health (history of chronic liver disease, elevated 
baseline AST, and HCV co-infection) were co-linear. Final multivariable models included 
only the predictors that contributed to the best model fit as determined by the minimized 
Akaike information criterion. We estimated attributable risk percentages for statistically 
significant predictors in our multivariable logistic regression models.
RESULTS
A total of 6862 adult participants in the PREVENT TB study took at least one dose of the 
study treatment: respectively 3317 (48%) and 3545 (52%) were prescribed 9H (9 months of 
daily INH) and 3HP. Baseline AST evaluation was conducted for 76% of all study 
participants, regardless of study regimen, with baseline AST results reported for the majority 
of participants from all trial sites except Brazil and California, USA (data not shown). 
Repeated AST monitoring (i.e., at least two AST results reported) during the study phase 
was conducted for 37% of participants (2558/6862), 40% of those on 9H (1312/3317) and 
35% of those on 3HP (1246/3545, RR 1.25, 95%CI 1.06–1.20; χ2 P = 0.0002).
Treatment-limiting hepatotoxicity occurred four times more frequently in those receiving 9H 
than 3HP among all participants (9H 1.9% vs. 3HP 0.4%, RR 4.42, 95%CI 2.52–7.75, χ2 P 
< 0.001), as well as among those with symptomatic (9H 1.3% vs. 3HP 0.3%, RR 4.51, 
95%CI 2.27–8.97, χ2 P < 0.001) and asymptomatic (9H 0.6% vs. 3HP 0.1%, RR 4.10, 
95%CI 1.53–11.0, χ2 P = 0.002) hepatotoxicity. In the nested study, there were 49 cases, of 
whom 35 were symptomatic (27 on 9H, 8 on 3HP) and 14 were asymptomatic (all on 9H), 
and 243 controls. No hospitalizations or deaths were associated with hepatotoxicity.
The clinical and demographic characteristics of the 6862 persons in the study population and 
the 292 participants enrolled in the nested study are shown in Appendix Table A.1.* Among 
the PREVENT TB study participants, those who developed any hepatotoxicity or 
symptomatic hepatotoxicity tended to be older, female, white, and non-Hispanic. In addition, 
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most had elevated baseline AST, a history of chronic liver disease or alcohol abuse, reported 
current injection drug use or cigarette smoking, and were receiving 9H (Appendix Table A.
1). Both cases and controls in the nested study were similar to non-enrolled cases and 
controls on all medical and social factors assessed (data not shown).
Within various clinical or demographic strata, persons who received 3HP consistently had a 
lower cumulative incidence of hepatotoxicity than those who received 9H (Appendix Table 
A.2). Persons administered 9H who developed hepatotoxicity received a median 4.5 mg/kg 
dose of INH compared to a 4.0 mg/kg dose received by those without hepatotoxicity 
(Wilcoxon signed-rank test P = 0.001). There were no significant differences in median 
mg/kg weekly dose of INH or RPT stratified by hepatotoxicity among persons on 3HP 
(hepatotoxicity, 10.9 mg/kg each of INH and RPT; no hepatotoxicity, 12.1 mg/kg each of 
INH and RPT, Wilcoxon signed-rank test P = 0.59).
The median number of days to the onset of treatment-limiting hepatotoxicity differed 
according to treatment regimen (9H median 101 days, inter-quartile range [IQR] 62–161; 
3HP median 22 days, IQR 19–49; Wilcoxon-Gehan P < 0.001). Similarly, days to the onset 
of treatment-limiting symptomatic or asymptomatic hepatotoxicity also differed by 
treatment regimen (symptomatic 9H 97 days, IQR 62–155; 3HP 23 days, IQR 19–40, 
Wilcoxon-Gehan P < 0.001; asymptomatic 9H 105 days, IQR 59–183; 3HP 21 days, IQR 
20–49, Wilcoxon-Gehan P < 0.001).
Permanent discontinuation of study treatment due to hepatotoxicity occurred more than five 
times more frequently among those taking 9H than 3HP (9H 1.7%, 3HP 0.3%, RR 5.54, 
95%CI 2.91–10.5, χ2 P < 0.001). Among those who restarted treatment, the median length 
of treatment interruption in days did not vary by treatment regimen (9H 36 days, IQR 21–44; 
3HP 15 days, IQR 13–30; Student’s t-test P = 0.48).
In the nested study, most cases (29/49, 59%) developed an AST 5–10 × ULN, and all events 
but one were grade 3 toxicities. The one serious adverse event (i.e., grade 4 toxicity) was in 
a Hispanic female participant assigned to 9H. She developed elevated AST (1025 U/l, 26× 
ULN), alanine aminotransferase (1468 U/l, 37× ULN) and bilirubin (2.9 mg/dl, 2.4× ULN) 
levels, with nausea, dark urine and pruritus after 89 doses of 9H; LTBI treatment was 
permanently discontinued. The majority of the cases presented with at least one symptom 
(37/49, 76%), of which fatigue was the most common (29/37, 76%).
In both the PREVENT TB and the nested study, female sex, history of chronic liver disease, 
elevated AST at LTBI treatment start, current or past alcohol use, and treatment with 9H 
were significantly associated with hepatotoxicity or symptomatic hepatotoxicity (Appendix 
Tables A.3 and A.4) on univariable analyses. Furthermore, increasing age and current or past 
injection drug use were associated with hepatotoxicity and symptomatic hepatotoxicity, 
ethnicity was associated with hepatotoxicity, and race with symptomatic hepatotoxicity in 
the PREVENT TB study, and with HCV co-infection with treatment-limiting hepatotoxicity 
in the nested study (Appendix Tables A.3 and A.4).
*The appendix is available in the online version of this article, at http://www.ingentaconnect.com/content/iuatld/ijtld/
2015/00000019/00000009/art00008
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In a multivariable analysis of risk factors for hepatotoxicity in the PREVENT TB study, 
increasing age, female sex, White race, non-Hispanic ethnicity, low body mass index (BMI), 
history of chronic liver disease, elevated AST at LTBI treatment start, and receipt of 9H 
were independently associated with an increased risk of hepatotoxicity (Appendix Table A.
2). The combined attributable risk for the presence of any of these factors was 56% (95%CI 
50–61). In an analysis of symptomatic hepatotoxicity, the same risk factors were associated 
with hepatotoxicity, except low BMI (Table), with a combined attributable risk of 61% 
(95%CI 54–66). In a multivariable analysis of risk factors in the nested study, when 
controlling for factors significant in the parent study except for age, HCV co-infection was 
an independent risk factor for hepatotoxicity, with an attributable risk of 51% (Appendix 
Table A.4).
DISCUSSION
Our study provides contemporary estimates of the incidence of and risk factors for 
hepatotoxicity during treatment for LTBI with 9H or 3HP under clinical trial conditions, and 
suggests that 3HP is less hepatotoxic than 9H and may be preferred in persons at increased 
risk of hepatotoxicity. The incidence of hepatotoxicity in persons treated with 9H was 
comparable to rates previously reported for daily INH.11,12 In contrast, the incidence of any 
hepatotoxicity or symptomatic hepatotoxicity among persons treated with 3HP in this study 
was significantly lower than that among those who received 9H. Although rare, severe liver 
injury and death are well-documented adverse effects of anti-tuberculosis drugs used for 
LTBI treatment, particularly INH.12,13 The participants in the PREVENT TB clinical trial 
had frequent interactions with health care providers, which may explain why more severe 
toxicity was not observed.14
The data from the PREVENT TB study allowed us to characterize the incidence of 
treatment-limiting hepatotoxicity and associated risk factors. The case-control study allowed 
us to focus on the specific role of HCV co-infection in treatment-limiting hepatotoxicity. 
Data from the PREVENT TB study demonstrated that participants with a history of chronic 
liver disease or elevated AST upon initiating LTBI treatment have an increased incidence of 
hepatotoxicity. This incidence was substantial for patients receiving 9H, but lower among 
those receiving 3HP. Also consistent with other studies, we found hepatotoxicity to be 
associated with increasing age, elevated AST at LTBI treatment start, and 9H.2,6 The nested 
study demonstrated that HCV co-infection was independently associated with 
hepatotoxicity. This association had been previously documented only among injection drug 
users, but even among this population the association has not been a consistent finding.15,16 
Furthermore, female sex, white race, and non-Hispanic ethnicity were identified as risk 
factors for hepatotoxicity, findings that have not been commonly described.17
Our results, combined with this prior work, suggest that close clinical monitoring is 
required, not only of persons of increased age and those with a history of chronic liver 
disease, but also of women and persons of White race and non-Hispanic ethnicity. Although 
lower BMI was found to be a risk factor, the median BMI of 26 kg/m2 among persons with 
hepatotoxicity was not consistent with malnutrition.
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Our study had two main limitations. First, AST monitoring differed by treatment regimen, 
with those on 9H being more likely to have two or more AST evaluations. There was thus 
potential for undetected asymptomatic hepatotoxicity, particularly among those on 3HP. Our 
RR estimates for 9H with any hepatotoxicity may therefore have been an overestimation. 
However, the RR estimates for 9H with any or symptomatic hepatotoxicity are very similar, 
suggesting minimal overestimation of the RR in our study. Second, this study was conducted 
in the context of a clinical trial. As patient selection (and self-selection) and monitoring may 
not reflect populations treated in operational settings, our observed incidence of 
hepatotoxicity might not accurately represent findings in program conditions.
LTBI treatment in all patients should include a discussion and evaluation of the risk of drug-
induced liver injury including hepatotoxicity, including chronic ethanol consumption, known 
viral hepatitis, pre-existing liver disease, post-partum within 3 months, concomitant 
hepatotoxic medication and previous abnormal liver enzymes.6 Furthermore, evaluation of 
AST at treatment initiation may help identify persons at increased risk of hepatotoxicity.
The possibility of severe hepatitis and liver dysfunction should be considered when deciding 
whether a patient with HCV is a candidate for LTBI treatment. If treatment is initiated, an 
adverse event clinical monitoring plan should be put in place. Given that 3HP is as effective 
as 9H,8,18 these results add to the growing body of evidence that 3HP may be a preferred 
choice for the treatment of LTBI, particularly among those patients who are at high risk of 
hepatotoxicity.
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APPENDIX
Table A.1
Demographic and clinical characteristics of adults enrolled in PREVENT TB and the nested 
case-control study























Age, years, median [IQR] 44 [34–52] 44 [33–52] 47 [37–50] 37 [28–48] 44 [33–52] 46 [32–53]
Female sex 49 (64) 36 (69) 12 (50) 3065 (45) 33 (67) 107 (44)
Race
 White 52 (68) 39 (75) 13 (54) 3799 (56) 35 (67) 121 (60)
 Black 13 (17) 8 (15) 5 (21) 1780 (26) 10 (20) 76 (31)
 Asian/Pacific Islander 6 (7.8) 2 (3.9) 4 (17) 887 (13) 4 (8.2) 32 (13)
 North American Indian 2 (2.6) 1 (1.9) 0 (0) 109 (1.6) 0 (0) 7 (2.9)
 Other 4 (5.2) 2 (3.9) 2 (8.3) 210 (3.1) 2 (4.1) 7 (2.9)
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 Hispanic 25 (32) 16 (31) 9 (37) 2666 (39) 11 (22) 62 (25)
 Non-Hispanic 51 (66) 36 (69) 14 (58) 3591 (53) 37 (76) 144 (59)
 Not applicable (not in 
the United States or 
Canada) 1 (1.3) 0 (0) 1 (4.2) 528 (7.8) 1 (2.0) 37 (15)
Health factors
 BMI, kg/m2, median 
[IQR]
26 [23–28] 26 [23–28] 25 [23–28] 27 [24–31] 26 [23–30] 28 [24–31]
 HIV status
  Non-infected 41 (53) 25 (48) 15 (63) 3366 (50) 31 (63) 132 (54)
  Infected 2 (2.6) 1 (1.9) 1 (4.2) 149 (2.2) 2 (4.1) 9 (3.7)
  Unknown 34 (44) 26 (50) 8 (33) 3270 (48) 16 (33) 102 (42)
 History of chronic liver 
disease
15 (19) 10 (19) 5 (21) 322 (4.8) 11 (20) 16 (6.6)
 Elevated baseline AST 21/72 (29) 9/48 (19) 12/23 (52) 369/5151 (7.2) 11/46 (24) 15/168 (8.9)
Hepatitis serology results‡
 Hepatitis B virus co-
infection
— — — — 0 (0) 3 (1.2)
 Hepatitis C virus co-
infection
— — — — 12 (24) 23 (9.5)
Self-reported social factors
 Homeless >6 months 6 (7.8) 5 (9.6) 1 (4.2) 495 (7.3) 4 (8.2) 24 (9.9)
 Unemployed >12 months 10 (13) 7 (13) 3 (13) 769 (11) 7 (14) 25 (10)
 Correctional institute >1 
month
7 (9.1) 3 (5.8) 4 (17) 377 (5.6) 3 (6.1) 18 (7.4)
 Current or past alcohol use
  None 28 (36) 22 (42) 6 (25) 3107/6777 (46) 17 (35) 119 (49)
  Use 36 (47) 21 (40) 14 (58) 3147/6777 (47) 24 (49) 110 (45)
  Abuse 13 (17) 9 (17) 4 (17) 469/6777 (6.9) 8 (16) 14 (5.8)
 Current or past IDU 10 (13) 8 (15) 2 (8.3) 254/6776 (3.8) 5 (10) 15 (6.2)
 Current cigarette smoker 28 (36) 18 (35) 10 (42) 1977 (29) 19 (39) 89 (35)
Anti-tuberculosis treatment factors
 Indication for TLTBI§
  Close contact 50 (65) 31 (60) 19 (79) 4711 (69) 29 (59) 181 (74)
  Recent converter 25 (32) 19 (37) 5 (21) 1798 (27) 18 (37) 50 (21)
  HIV-infected 0 (0) 0 (0) — 107 (1.6) 0 (0) 8 (3.3)
  Fibrosis on chest X-
ray
2 (2.6) 2 (3.9) — 169 (2.5) 2 (4.1) 4 (1.7)
 9H 62 (81) 42 (81) 19 (80) 3353 (48) 41 (84) 95 (39)
*
Hepatotoxicity was defined as serum AST >3 × ULN with symptoms of nausea, vomiting, jaundice or fatigue, or AST >5 
× ULN regardless of symptoms.
†
Symptoms were not assessed for one participant.
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Hepatitis B and C serological and NAT tests were performed systematically only for participants in the nested case-control 
study.
§
Subjects were counted only once in the order presented. The total number of HIV-infected persons who were enrolled is 
listed separately in this table.
BMI = body mass index; HIV = human immunodeficiency virus; AST = aspartate aminotransferase; IDU = injection drug 
user; TLTBI = treatment for latent tuberculous infection; 9H =9 months of self-administered daily isoniazid at 5–15 mg/kg 
rounded to the nearest 50 mg, with a maximum dose of 300 mg; ULN = upper limit of normal; NAT = nucleic acid testing.
Table A.2
Treatment-limiting hepatotoxicity cumulative incidence (95%CI) by treatment arm among 
adults enrolled in the Tuberculosis Trials Consortium PREVENT TB study
All 9H 3HP
n/N % (95%CI) n/N % (95%CI) n/N % (95%CI)
Overall* 77/6862 1.1 (0.9–1.4) 61/3317 1.8 (1.4–2.3) 15/3545 0.4 (0.2–0.6)
Treatment permanently discontinued 68/6862 1.0 (0.8–1.2) 57/3317 1.7 (1.3–2.2) 11/3545 0.3 (0.1–0.5)
Symptomatic 52/6862 0.8 (0.6–1.0) 42/3317 1.3 (0.9–1.6) 10/3545 0.3 (0.1–0.5)
Asymptomatic 24/6862 0.3 (0.2–0.5) 19/3317 0.6 (0.3–0.8) 5/3545 0.1 (0.02–0.3)
Demographic factors
 Female sex 49/3114 1.6 (1.1–2.0) 40/1528 2.6 (1.8–3.4) 9/1586 0.6 (0.2–0.9)
 Male sex 28/3748 0.7 (0.5–1.0) 22/1789 1.2 (0.7–1.7) 6/1959 0.3 (0.1–0.6)
 Race
  White 52/3851 1.4 (1.0–1.7) 44/1873 2.3 (1.7–3.0) 8/1978 0.4 (0.1–0.7)
  Black 13/1793 0.7 (0.3–1.1) 8/873 0.9 (0.3–1.5) 5/920 0.5 (0.1–1.0)
  Asian/Pacific Islander 6/893 0.7 (0.1–1.2) 5/443 1.1 (0.1–2.1) 1/450 0.2 (0–0.7)
  North American Indian 2/111 1.8 (0–4.3) 2/31 6.5 (0–15) 0/80 0
  Other 4/214 1.9 (0–3.7) 3/97 3.1 (0–6.5) 1/117 0.9 (0–2.5)
 Ethnicity
  Hispanic 25/2691 0.9 (0.6–1.3) 21/1283 1.6 (0.9–3.0) 4/1408 0.3 (0–0.6)
  Not Hispanic 51/3642 1.4 (1.0–1.8) 40/1770 2.3 (1.6–3.0) 11/1872 0.6 (0.2–0.9)
  Not applicable (not US or 
Canada)
1/529 0.2 (0–0.6) 1/264 0.4 (0–1.1) 0/265 0
Health factors
 HIV status
  Non-infected 41/3407 1.2 (0.8–1.5) 32/1688 1.9 (1.2–2.5) 9/1719 0.5 (0.2–0.9)
  Infected 2/151 1.3 (0–3.1) 1/78 1.3 (0–3.8) 1/73 1.4 (0–4.0)
  Unknown 34/3304 1.0 (0.7–1.4) 29/1551 1.9 (1.2–2.5) 5/1753 0.3 (0–0.5)
 History of chronic liver disease 15/337 4.5 (2.2–6.7) 13/171 7.6 (3.6–12) 2/166 1.2 (0–2.9)
 Elevated baseline AST 21/390 5.4 (3.1–7.6) 17/188 9.0 (4.9–13.0) 4/202 2.0 (0.1–3.9)
Self-reported social factors
 Homeless >6 months 6/501 1.2 (0.2–2.2) 6/214 2.8 (0.6–5.0) 0/287 0
 Unemployed >12 months 10/779 1.3 (0.5–2.1) 9/369 2.4 (0.9–4.0) 1/410 0.2 (0–0.7)
 Correctional institute >1 month 7/384 1.8 (0.5–3.2) 6/169 3.6 (0.8–6.3) 1/215 0.5 (0–1.4)
 Current or past alcohol use
  None 28/3135 0.9 (0.6–1.2) 21/1475 1.4 (0.8–2.0) 7/1660 0.4 (0.1–0.7)
  Use 36/3210 1.1 (0.8–1.5) 30/1616 1.9 (1.2–2.5) 6/1594 0.4 (0.1–0.7)
  Abuse 13/509 2.6 (1.2–3.9) 11/222 5.0 (2.1–7.8) 2/287 0.7 (0–1.7)
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n/N % (95%CI) n/N % (95%CI) n/N % (95%CI)
 Current or past IDU 10/264 4.0 (1.7–6.3) 8/130 6.2 (2.0–10) 2/134 1.5 (0–3.5)
 Current cigarette smoker 28/2005 1.4 (0.9–1.9) 24/959 2.5 (1.5–3.5) 4/1046 0.4 (0–0.8)
TB treatment factors
 Indication for TLTBI†
  Close contact 50/4761 1.1 (0.8–1.3) 42/2252 1.9 (1.3–2.4) 8/2506 0.3 (0.1–0.5)
  Recent converter 25/1823 1.4 (0.8–1.9) 18/924 1.9 (1.1–2.8) 7/899 0.8 (0.2–1.4)
  HIV-infected 0/107 0 0/52 0 0/55 0
  Fibrosis on chest X-ray 2/171 1.2 (0–2.8) 2/89 2.2 (0–5.3) 0/82 0
*
Symptoms were not assessed for one participant.
†
Subjects were counted only once in the order presented. The total number of HIV-infected persons who were enrolled is 
listed separately in this table.
CI=confidence interval; 9H=9 months of self-administered daily isoniazid at 5–15 mg/kg rounded to the nearest 50 mg, 
with a maximum dose of 300 mg; 3HP= 3 months of directly-observed once weekly 900 mg rifapentine plus isoniazid at 
15–25 mg/kg rounded to the nearest 50 mg, with a maximum dose of 900 mg; HIV = human immunodeficiency virus; AST 
=aspartate aminotransferase; IDU = injection drug user; TLTBI = treatment for latent tuberculous infection.
Table A.3
Univariable analyses of risk factors for treatment-limiting hepatotoxicity in the PREVENT 
TB study
All hepatotoxicity* Symptomatic hepatotoxicity*
RR (95%CI)† P value† RR (95%CI)† P value†
Demographic factors
 Age, per year increase 1.03 (1.01–1.04) <0.0001 1.03 (1.01–1.04) 0.002
 Female sex 2.11 (1.33–3.34) 0.002 2.71 (1.51–4.88) 0.009
 Race 0.07 0.04
  White 1.00 (reference) 1.00 (reference)
  Black 0.54 (0.30–0.98) 0.44 (0.21–0.94)
  Asian 0.50 (0.21–1.15) 0.22 (0.05–0.92)
  Other 1.37 (0.59–3.16) 0.92 (0.28–2.95)
 Ethnicity 0.04 0.09
  Hispanic 1.00 (reference) 1.00 (reference)
  Non-Hispanic 1.51 (0.94–2.42) 1.66 (0.92–3.00)
  Not applicable (not US or Canada) 0.20 (0.03–1.50)
Health factors
 BMI, per kg/m2 increase 0.97 (0.93–1.01) 0.10 0.97 (0.93–1.02) 0.24
 HIV status 0.77 0.96
  Non-infected 1.00 (reference) 1.00 (reference)
  Infected 1.10 (0.27–4.51) 0.90 (0.12–6.63)
  Unknown 0.86 (0.54–1.34) 1.07 (0.62–1.85)
 History of chronic liver disease 4.68 (2.69–8.15) <0.0001 4.67 (2.36–9.22) <0.0001
 Elevated baseline AST 5.10 (3.10–8.39) <0.0001 2.94 (1.44–6.03) 0.003
Social factors
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All hepatotoxicity* Symptomatic hepatotoxicity*
RR (95%CI)† P value† RR (95%CI)† P value†
 Homeless >6 months 1.07 (0.47–2.46) 0.87 1.34 (0.54–3.37) 0.52
 Unemployed >12 months 1.17 (0.60–2.26) 0.65 1.22 (0.54–2.68) 0.63
 Correctional institute >1 month 1.69 (0.78–3.64) 0.18 1.04 (0.33–3.32) 0.95
 Current or past alcohol use 0.006 0.03
  None 1.00 (reference) 1.00 (reference)
  Use 1.26 (0.77–2.05) 0.93 (0.52–1.70)
  Abuse 2.86 (1.49–5.48) 2.53 (1.17–5.47)
 Current or past IDU 3.73 (1.94–7.16) <0.0001 4.56 (2.17–9.58) <0.0001
 Current cigarette smoker 1.38 (0.87–2.20) 0.17 1.28 (0.72–2.27) 0.39
TB treatment factors
 Indication for TLTBI‡ 0.55 0.23
  Close contact 1.00 (reference) 1.00 (reference)
  Recent converter 1.31 (0.81–2.10) 1.60 (0.91–2.82)
  Fibrosis on chest X-ray 1.11 (0.27–4.54) 1.79 (0.43–7.41)
 Treatment with 9H 4.42 (2.52–7.75) <0.0001 4.51 (2.27–8.97) <0.0001
*
Hepatotoxicity was defined as serum AST >3 × ULN with symptoms of nausea, vomiting, jaundice or fatigue or AST >5 
× ULN regardless of symptoms.
†
P values are from the Wald χ2 test. RRs are estimated through log-binomial regression.
‡
Subjects were counted only once in the order presented. The total number of HIV-infected persons who were enrolled is 
listed separately in this table.
RR =risk ratio; CI =confidence interval; BMI =body mass index; HIV =human immunodeficiency virus; AST =aspartate 
aminotransferase; IDU =injection drug user; TLTBI =treatment for latent tuberculous infection; 9H =9 months of self-
administered daily isoniazid at 5–15 mg/kg rounded to the nearest 50 mg, with a maximum dose of 300 mg; ULN = upper 
limit of normal.
Table A.4
Univariable and multivariable analyses of risk factors for treatment-limiting hepatotoxicity* 
in the nested case-control study
Univariable analysis Multivariable analysis
OR (95%CI)† P value† OR (95%CI)† P value† Attributable risk‡ %
Demographic factors
 Age, per year increase 1.00 (0.98–1.02) 0.97
 Female sex 2.62 (1.37–5.01) 0.003 2.75 (1.28–5.91) 0.001 50
 Race 0.18 0.01
  White 1.00 (reference) 1.00 (reference) 41
  Black 0.48 (0.23–1.04) 0.23 (0.08–0.63)
  Asian 0.46 (0.15–1.39) 0.19 (0.05–0.72)
  Other 0.52 (0.11–2.42) 0.97 (0.15–6.47)
 Ethnicity 0.07 0.005
  Hispanic 1.00 (reference) 1.00 (reference) 43
 Non-Hispanic 1.45 (0.69–3.02) 2.97 (1.13–7.86)
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Univariable analysis Multivariable analysis
OR (95%CI)† P value† OR (95%CI)† P value† Attributable risk‡ %
 Not applicable (not US or 
Canada)
0.15 (0.02–1.23) 0.14 (0.02–1.30)
Health factors
 BMI, per kg/m2 increase 0.95 (0.90–1.01) 0.08 0.92 (0.86–0.99) 0.02
 HIV status 0.48
  Non-infected 1.00 (reference)
  Infected 0.95 (0.20–4.60)
  Unknown 0.68 (0.35–1.29)
 History of chronic liver 
disease
3.64 (1.54–8.60) 0.005 — 0.79
 Elevated baseline AST 3.21 (1.36–7.58) 0.006
 Hepatitis B virus co-
infection
0.69 (0.04–13.7) 1.00
 Hepatitis C virus co-
infection
3.10 (1.42–6.77) 0.003 3.24 (1.12–9.34) 0.03 51
Social factors
 Homeless >6 months 0.81 (0.27–2.45) 0.71
 Unemployed >12 months 1.45 (0.59–3.58) 0.42
 Correctional institute >1 
month
0.82 (0.25–2.88) 0.75
 Current or past alcohol use 0.03 — 0.06
  None 1.00 (reference) —
  Use 1.57 (0.78–2.99) —
  Abuse 4.00 (1.46–10.9) —
 Current or past IDU 1.72 (0.59–4.98) 0.31 — 0.10
 Current cigarette smoker 1.16 (0.61–2.18) 0.65
Anti-tuberculosis treatment factors
 Indication for TLTBI§ 0.04 — 0.94
  Close contact 1.00 (reference) —
  Recent converter 2.25 (1.15–4.38) —
  Fibrosis on chest X-ray 3.12 (0.55–17.8) —
 Treatment with 9H 7.98 (3.59–17.8) <0.0001 9.20 (3.79–22.4) <0.0001 79
*
Hepatotoxicity was defined as serum AST >3 × ULN with symptoms of nausea, vomiting, jaundice or fatigue or AST >5 
× ULN regardless of symptoms.
†
P values are from the Wald χ2 test. ORs are estimated through logistic regression. Only participant factors with a 
univariable P < 0.20 were entered into the multivariable model, and only factors with a P ≤0.05 were retained in the final 
multivariable model. For the multivariable model, P values without an OR indicate terms that were entered into the model 
but not retained in the final model. Elevated baseline ASTwas not included in the multivariable model as data were missing 
in 27% of case-control participants.
‡
Calculated for White race and non-Hispanic ethnicity only, not all races and ethnicities.
§
Subjects were counted only once in the order presented. The total number of HIV-infected persons who were enrolled is 
listed separately in this table.
OR =odds ratio; CI =confidence interval; BMI =body mass index; HIV =human immunodeficiency virus; AST =aspartate 
aminotransferase; IDU =injection drug user; TLTBI =treatment for latent tuberculous infection; 9H =9 months of self-
administered daily isoniazid at 5–15 mg/kg rounded to the nearest 50 mg, with a maximum dose of 300 mg; ULN = upper 
limit of normal.
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